Krystal Biotech, Inc. - COMMON STOCK (KRYS)

Historical Holders from Q3 2017 to Q3 2025

Symbol: KRYS on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 29,067,614
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 27,965,035
Holdings value: $4,936,705,319
% of all portfolios: 0.006%
Number of holders: 280
Number of buys: 147
Number of sells: -119
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Krystal Biotech, Inc. - COMMON STOCK (KRYS)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
STATE STREET CORP	4.4%		$218,154,766		1,278,975		STATE STREET CORPORATION	31 Dec 2024

Institutional Holders of Krystal Biotech, Inc. - COMMON STOCK (KRYS)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	27,965,035	$4,936,705,319	+$83,533,504	$110,317,117	$42,491,739	$176.53	280
2025 Q2	27,659,439	$3,802,977,476	-$846,440	$66,603,062	$57,255,782	$137.46	274
2025 Q1	27,342,861	$4,929,918,497	-$51,223,771	$17,624,068	$53,817,810	$180.3	298
2024 Q4	27,774,030	$4,351,782,009	-$92,533,890	$36,515,282	$60,779,090	$156.66	264
2024 Q3	28,280,954	$5,147,915,246	-$55,463,849	$66,162,636	$87,880,282	$182.03	281
2024 Q2	28,529,838	$5,239,051,095	+$658,436,118	$31,549,352	$49,491,380	$183.64	245
2024 Q1	25,223,190	$4,487,798,716	+$175,442,652	$125,138,569	$80,032,650	$177.93	233
2023 Q4	24,418,337	$3,029,453,570	+$42,716,131	$89,769,816	$41,510,476	$124.06	194
2023 Q3	23,797,985	$2,760,663,293	+$92,606,023	$20,856,800	$18,803,600	$116	187
2023 Q2	23,039,160	$2,704,675,917	+$256,730,169	$16,129,570	$18,792,107	$117.4	182
2023 Q1	20,979,177	$1,678,957,589	+$9,326,151	$9,919,434	$5,524,140	$80.06	159
2022 Q4	20,961,146	$1,660,575,264	-$15,716,124	$20,320,212	$2,954,906	$79.22	153
2022 Q3	20,879,536	$1,455,390,527	+$2,509,281	$10,773,000	$3,094,000	$69.7	141
2022 Q2	20,782,487	$1,364,495,044	+$17,501,639	$2,305,000	$6,402,000	$65.66	129
2022 Q1	20,551,109	$1,367,525,309	+$24,889,158	$2,657,000	$4,025,000	$66.54	129
2021 Q4	19,309,579	$1,350,723,574	+$209,084,528	$18,356,000	$15,639,000	$69.95	135
2021 Q3	16,287,424	$850,358,590	-$12,114,445	$19,099,000	$35,274,000	$52.21	112
2021 Q2	16,400,636	$1,115,239,700	-$7,228,383	$5,947,000	$3,900,000	$68	113
2021 Q1	16,474,358	$1,268,577,569	+$201,515,888	$1,432,000	$4,314,000	$77.04	113
2020 Q4	13,913,023	$835,272,340	-$16,214,267	$0	$2,334,000	$60	107
2020 Q3	14,383,109	$619,123,442	+$11,279,105	$1,050,000	$431,000	$43.05	98
2020 Q2	14,124,381	$585,026,548	+$106,373,347	$1,098,000	$1,034,000	$41.42	108
2020 Q1	11,507,819	$497,600,700	-$9,385,943			$43.24	88
2019 Q4	11,391,925	$630,888,478	+$15,766,941			$55.38	89
2019 Q3	11,182,639	$388,328,616	+$48,273,351			$34.73	83
2019 Q2	9,765,134	$393,197,420	+$130,560,730			$40.27	75
2019 Q1	6,652,555	$218,869,000	+$15,470,940			$32.9	56
2018 Q4	6,208,589	$129,016,000	+$73,086,744			$20.78	45
2018 Q3	2,717,290	$47,597,000	+$6,006,830			$17.58	21
2018 Q2	2,390,244	$35,543,000	-$7,828,421			$14.87	16
2018 Q1	3,076,255	$31,040,000	-$1,629,988			$10.09	12
2017 Q4	3,236,349	$34,047,000	+$1,027,245			$10.52	13
2017 Q3	3,142,571	$31,331,000	+$31,331,000			$9.97	13